ストックスクリーナーアプリを入手
0.831
6.36%
-0.0564
Oncolytics Biotech Inc (ONCY) 最新ニュース
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector - Baystreet.ca
Oncolytics Biotech (TSE:ONC) Stock Price Up 14.5%Here's What Happened - MarketBeat
From Crisis To Opportunity: How Advances In Immunotherapy Are Shaping The Oncology Sector - MENAFN.COM
Stocks In Play: Oncolytics Biotech Inc. - Barchart
Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail
Early-Onset Cancer Trends Spark Interest In Promising Oncology Pipelines - MENAFN.COM
Oncolytics Biotech Inc. - Baystreet.ca
Early-Onset Cancer Trends Spark Interest in Promising Oncology Pipelines - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium - Barchart
Oncolytics Biotech's SWOT analysis: pelareorep progress boosts stock outlook - Investing.com
Oncolytics Biotech (TSE:ONC) Sets New 12-Month LowWhat's Next? - MarketBeat
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September - The Eastern Progress Online
Oncolytics Biotech (NASDAQ:ONCY) Trading Down 2.1%Should You Sell? - MarketBeat
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights - The Eastern Progress Online
Oncolytics Biotech's SWOT analysis: pela's potential buoys speculative stock By Investing.com - Investing.com Nigeria
Oncolytics Biotech's SWOT analysis: pela's potential buoys speculative stock - Investing.com India
Oncolytics Biotech's SWOT analysis: cancer drug developer's stock faces pivotal year - Investing.com
Oncolytics Biotech Inc. Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial?s New Pancreatic Cancer Cohort - Marketscreener.com
Stocks In Play: Oncolytics Biotech Inc By Baystreet.ca - Investing.com Canada
Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort - Barchart
Oncolytics Biotech® Reports Completion of Initial Safety Phase E - GuruFocus.com
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend - cnhinews.com
Biotech Advances Drive Cancer Research As Global Rates Continue Upward Trend - MENAFN.COM
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend - Benzinga
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference - Quantisnow
Cancer firm Replimune readies $125 million offering - The Pharma Letter
Oncolytics Biotech® to Host Conference Call to Discuss Third Qua - GuruFocus.com
HC Wainwright Has Negative Estimate for ONCY FY2024 Earnings - MarketBeat
HC Wainwright Issues Negative Forecast for TSE:ONC Earnings - MarketBeat
Leede Financial Weighs in on TSE:ONC FY2024 Earnings - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Downgraded to Moderate Buy Rating by Leede Financial - Defense World
Oncolytics Biotech (TSE:ONC) Upgraded at Raymond James - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Upgraded at Raymond James - Defense World
Oncolytics Biotech (TSE:ONC) Upgraded by Raymond James to Moderate Buy Rating - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Downgraded to "Moderate Buy" Rating by Leede Financial - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Upgraded by Raymond James - MarketBeat
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):